The case for & against
Bull & Bear analysis
Bearish
AbCellera Biologics Inc. (NASDAQ: ABCL) is an emerging biopharmaceutical company that specializes in developing innovative therapies, particularly in women's health, oncology, and immunology. The company operates primarily within the antibody discovery space, leveraging advanced technologies to accelerate the development of novel treatments. Notably, AbCellera's lead candidate ABCL635 is aimed at addressing moderate-to-severe menopausal hot flashes, positioning the company within the growing market for non-hormonal therapies.
Bull says
- ↑Maintains $565M cash and equivalents, funding R&D through 2027
- ↑Phase 2 ABCL635 trial showed substantial vasomotor symptom reduction
- ↑Vertex and Jazz deals provided $110M upfront and $4B+ in milestones
- ↑Strong momentum factors and liquidity drive investor interest
- ↑Expanding non-hormonal women's health market boosts commercial potential
- ↑Potential undervaluation given cash runway and de-risked pipeline
Bear says
- ↓Q2 revenue fell to $4M; net loss rose to $55M
- ↓Negative profitability and earnings-yield factors highlight inefficiency
- ↓Volatile stock may see large price swings on trial updates
- ↓Regulatory approval timing for ABCL635 remains uncertain, risking delays
- ↓High short interest indicates skepticism on partnership milestones
- ↓Ongoing operating losses threaten sustainability without revenue ramp
Investment themes with ABCL
Recent IPOs↓ -2.25%
Companies that recently went public
SNOW · PLTR · PTON
Earnings Call · Q1 2024 · Mgmt. Guidance
Updated 05-09-2025bullish
Transcript signals
Bull points
- As AbCellera continues to evolve into a clinical biotech company, we are directing our resources towards three main priorities.
- Our first priority is advancing our internal pipeline, including ABCL635 and ABCL575. Both programs are in manufacturing and IND enabling studies and are on track for IND submissions in 2025.
- We are on track to start our first engineering runs at our facility next year.
Bear points
- Looking at earnings, we are reporting a net loss of roughly $41 million for the quarter, compared to a loss of $40 million in the same quarter of last year.
- In terms of earnings per share, this quarter result works out to a loss of $0.14 per share on a basic and diluted basis.
Read full transcript analysis ›